
Australia has one of the highest rates of asbestos-associated diseases. RIOMeso is the 1st detailed report of real-world outcomes for ipilimumab/nivolumab for mesothelioma in Australia, revealing significant toxicity & less prominent survival benefit.bit.ly/46AuJsR #LCSM


















